ES2377015T3 - Utilización de la alfa-lactoalbúmina para la regulación de la glucemia - Google Patents
Utilización de la alfa-lactoalbúmina para la regulación de la glucemia Download PDFInfo
- Publication number
- ES2377015T3 ES2377015T3 ES07731348T ES07731348T ES2377015T3 ES 2377015 T3 ES2377015 T3 ES 2377015T3 ES 07731348 T ES07731348 T ES 07731348T ES 07731348 T ES07731348 T ES 07731348T ES 2377015 T3 ES2377015 T3 ES 2377015T3
- Authority
- ES
- Spain
- Prior art keywords
- lactoalbumin
- use according
- proteins
- weight
- diet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000004407 Lactalbumin Human genes 0.000 title claims abstract description 12
- 108090000942 Lactalbumin Proteins 0.000 title claims abstract description 12
- 235000021241 α-lactalbumin Nutrition 0.000 title claims abstract description 12
- 230000033228 biological regulation Effects 0.000 title abstract description 16
- 230000002641 glycemic effect Effects 0.000 title description 18
- 235000005911 diet Nutrition 0.000 claims abstract description 62
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 32
- 239000008103 glucose Substances 0.000 claims abstract description 32
- 239000000203 mixture Substances 0.000 claims abstract description 31
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 26
- 206010022489 Insulin Resistance Diseases 0.000 claims abstract description 21
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 66
- 230000037213 diet Effects 0.000 claims description 55
- 235000018102 proteins Nutrition 0.000 claims description 35
- 102000004169 proteins and genes Human genes 0.000 claims description 35
- 108090000623 proteins and genes Proteins 0.000 claims description 35
- 229960003180 glutathione Drugs 0.000 claims description 33
- 108010024636 Glutathione Proteins 0.000 claims description 31
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 28
- 210000004369 blood Anatomy 0.000 claims description 23
- 239000008280 blood Substances 0.000 claims description 23
- 229930006000 Sucrose Natural products 0.000 claims description 22
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 22
- 239000005720 sucrose Substances 0.000 claims description 21
- 235000012054 meals Nutrition 0.000 claims description 17
- 230000000291 postprandial effect Effects 0.000 claims description 15
- 102000004877 Insulin Human genes 0.000 claims description 14
- 108090001061 Insulin Proteins 0.000 claims description 14
- 230000000694 effects Effects 0.000 claims description 14
- 229940125396 insulin Drugs 0.000 claims description 14
- 108010046377 Whey Proteins Proteins 0.000 claims description 12
- 102000007544 Whey Proteins Human genes 0.000 claims description 11
- 208000002705 Glucose Intolerance Diseases 0.000 claims description 10
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims description 10
- 230000015572 biosynthetic process Effects 0.000 claims description 9
- 238000003786 synthesis reaction Methods 0.000 claims description 9
- 239000005862 Whey Substances 0.000 claims description 8
- 235000007882 dietary composition Nutrition 0.000 claims description 7
- 238000011156 evaluation Methods 0.000 claims description 6
- 238000005259 measurement Methods 0.000 claims description 6
- 239000012141 concentrate Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 230000005764 inhibitory process Effects 0.000 claims description 4
- 235000021075 protein intake Nutrition 0.000 claims description 4
- 235000021119 whey protein Nutrition 0.000 claims description 4
- 108091006003 carbonylated proteins Proteins 0.000 claims description 3
- 238000007446 glucose tolerance test Methods 0.000 claims description 3
- 235000020256 human milk Nutrition 0.000 claims description 2
- 210000004251 human milk Anatomy 0.000 claims description 2
- 235000020246 buffalo milk Nutrition 0.000 claims 1
- 235000020247 cow milk Nutrition 0.000 claims 1
- 235000020251 goat milk Nutrition 0.000 claims 1
- 235000020254 sheep milk Nutrition 0.000 claims 1
- 230000000378 dietary effect Effects 0.000 abstract description 7
- 238000010521 absorption reaction Methods 0.000 abstract description 3
- 230000001413 cellular effect Effects 0.000 abstract description 2
- 235000013402 health food Nutrition 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 31
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 29
- 235000018417 cysteine Nutrition 0.000 description 29
- 235000013305 food Nutrition 0.000 description 23
- 229960004793 sucrose Drugs 0.000 description 18
- 102000014171 Milk Proteins Human genes 0.000 description 12
- 108010011756 Milk Proteins Proteins 0.000 description 12
- 235000021239 milk protein Nutrition 0.000 description 12
- 235000015872 dietary supplement Nutrition 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 210000004185 liver Anatomy 0.000 description 9
- 235000013336 milk Nutrition 0.000 description 8
- 239000008267 milk Substances 0.000 description 8
- 210000004080 milk Anatomy 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 201000001421 hyperglycemia Diseases 0.000 description 7
- 230000004155 insulin signaling pathway Effects 0.000 description 7
- 230000036542 oxidative stress Effects 0.000 description 7
- 235000000346 sugar Nutrition 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 230000009471 action Effects 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 6
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 6
- 150000008163 sugars Chemical class 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 4
- 108010028690 Fish Proteins Proteins 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 238000007410 oral glucose tolerance test Methods 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000009469 supplementation Effects 0.000 description 4
- 102000004506 Blood Proteins Human genes 0.000 description 3
- 108010017384 Blood Proteins Proteins 0.000 description 3
- 102000011632 Caseins Human genes 0.000 description 3
- 108010076119 Caseins Proteins 0.000 description 3
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 3
- 229960004308 acetylcysteine Drugs 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 210000000593 adipose tissue white Anatomy 0.000 description 3
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 3
- 235000021240 caseins Nutrition 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 235000008504 concentrate Nutrition 0.000 description 3
- 235000013365 dairy product Nutrition 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 229940076279 serotonin Drugs 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 108010053070 Glutathione Disulfide Proteins 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101001077604 Homo sapiens Insulin receptor substrate 1 Proteins 0.000 description 2
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 2
- 102100025087 Insulin receptor substrate 1 Human genes 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- 230000008727 cellular glucose uptake Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- 229960004874 choline bitartrate Drugs 0.000 description 2
- QWJSAWXRUVVRLH-UHFFFAOYSA-M choline bitartrate Chemical compound C[N+](C)(C)CCO.OC(=O)C(O)C(O)C([O-])=O QWJSAWXRUVVRLH-UHFFFAOYSA-M 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 235000020940 control diet Nutrition 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 235000021245 dietary protein Nutrition 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000550 effect on aging Effects 0.000 description 2
- 238000005265 energy consumption Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000003345 hyperglycaemic effect Effects 0.000 description 2
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 2
- 201000008980 hyperinsulinism Diseases 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 235000021309 simple sugar Nutrition 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 1
- MPPQGYCZBNURDG-UHFFFAOYSA-N 2-propionyl-6-dimethylaminonaphthalene Chemical compound C1=C(N(C)C)C=CC2=CC(C(=O)CC)=CC=C21 MPPQGYCZBNURDG-UHFFFAOYSA-N 0.000 description 1
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 description 1
- 229940000681 5-hydroxytryptophan Drugs 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 102000015781 Dietary Proteins Human genes 0.000 description 1
- 108010010256 Dietary Proteins Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 102000008192 Lactoglobulins Human genes 0.000 description 1
- 108010060630 Lactoglobulins Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 240000002129 Malva sylvestris Species 0.000 description 1
- 235000006770 Malva sylvestris Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000000516 activation analysis Methods 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 210000003486 adipose tissue brown Anatomy 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000006315 carbonylation Effects 0.000 description 1
- 238000005810 carbonylation reaction Methods 0.000 description 1
- 229940021722 caseins Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000021310 complex sugar Nutrition 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000011950 custard Nutrition 0.000 description 1
- 235000019543 dairy drink Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- LDCYZAJDBXYCGN-UHFFFAOYSA-N oxitriptan Natural products C1=C(O)C=C2C(CC(N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000135 prohibitive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000000276 sedentary effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 235000021195 test diet Nutrition 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Food Science & Technology (AREA)
- Obesity (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Polyamides (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0603810A FR2900342B1 (fr) | 2006-04-27 | 2006-04-27 | Utilisation de l'alpha-lactalbumine pour la regulation de la glycemie |
| FR0603810 | 2006-04-27 | ||
| PCT/FR2007/000689 WO2007128901A1 (fr) | 2006-04-27 | 2007-04-24 | Utilisation de l'alpha-lactalbumine pour la regulation de la glycemie |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2377015T3 true ES2377015T3 (es) | 2012-03-21 |
Family
ID=37478857
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES07731348T Active ES2377015T3 (es) | 2006-04-27 | 2007-04-24 | Utilización de la alfa-lactoalbúmina para la regulación de la glucemia |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8648039B2 (pl) |
| EP (1) | EP2029231B1 (pl) |
| AT (1) | ATE531426T1 (pl) |
| AU (1) | AU2007247025B2 (pl) |
| CA (1) | CA2650495C (pl) |
| DK (1) | DK2029231T3 (pl) |
| ES (1) | ES2377015T3 (pl) |
| FR (1) | FR2900342B1 (pl) |
| PL (1) | PL2029231T3 (pl) |
| WO (1) | WO2007128901A1 (pl) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2318021A4 (en) * | 2008-06-26 | 2012-10-31 | Healthlinx Ltd | PROTOCOLS FOR THE TREATMENT AND PREVENTION OF FAT SUPPORT AND COMPLICATIONS THEREOF |
| GB0905555D0 (en) * | 2009-03-31 | 2009-05-13 | Peptcell Ltd | Pharmaceutical agent |
| WO2010119088A2 (en) * | 2009-04-15 | 2010-10-21 | Bodo Melnik | Milk and milk-based products modified to exhibit a reduced insulinemic index and/or reduced mitogenic activity |
| CN113827707B (zh) * | 2021-09-30 | 2023-12-05 | 北京大学 | a-乳白蛋白在抑制冠状病毒中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3343141A1 (de) * | 1983-11-29 | 1985-06-05 | Hermann P.T. 7400 Tübingen Ammon | Verwendung von cystein-derivaten oder deren salzen, zur steigerung der insulinsekretion der langerhans'schen inseln der bauchspeicheldruese |
| DE69220374T2 (de) * | 1992-12-23 | 1998-01-15 | Campina Melkunie Bv | Verfahren zur Gewinnung von Alpha-Lactalbumin und Beta-Lactoglobulin aus einem Molkeproteinprodukt |
| BR9708656A (pt) * | 1996-04-12 | 2000-01-04 | Beth Israel Hospital | Barra suplementar para diabéticos |
| EP1228707A1 (en) * | 2001-02-01 | 2002-08-07 | Campina Melkunie B.V. | Use of alpha-lactalbumin as prebiotic agent |
| US20020147153A1 (en) * | 2001-02-14 | 2002-10-10 | Functional Foods, Inc. | Nutritional supplement to alleviate symptoms associated with reduced levels of serotonin |
| FR2875680B1 (fr) * | 2004-09-29 | 2010-08-20 | Veronique Marie-Pierre Peyrusson | Compose dietetique pour combattre le syndrome metabolique |
-
2006
- 2006-04-27 FR FR0603810A patent/FR2900342B1/fr active Active
-
2007
- 2007-04-24 EP EP07731348A patent/EP2029231B1/fr active Active
- 2007-04-24 PL PL07731348T patent/PL2029231T3/pl unknown
- 2007-04-24 WO PCT/FR2007/000689 patent/WO2007128901A1/fr active Application Filing
- 2007-04-24 US US12/298,417 patent/US8648039B2/en active Active
- 2007-04-24 CA CA2650495A patent/CA2650495C/fr active Active
- 2007-04-24 AU AU2007247025A patent/AU2007247025B2/en active Active
- 2007-04-24 ES ES07731348T patent/ES2377015T3/es active Active
- 2007-04-24 DK DK07731348.4T patent/DK2029231T3/da active
- 2007-04-24 AT AT07731348T patent/ATE531426T1/de active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2650495C (fr) | 2016-01-05 |
| FR2900342B1 (fr) | 2010-08-20 |
| US20090325872A1 (en) | 2009-12-31 |
| US8648039B2 (en) | 2014-02-11 |
| ATE531426T1 (de) | 2011-11-15 |
| EP2029231B1 (fr) | 2011-11-02 |
| FR2900342A1 (fr) | 2007-11-02 |
| AU2007247025A1 (en) | 2007-11-15 |
| PL2029231T3 (pl) | 2012-05-31 |
| AU2007247025B2 (en) | 2013-01-10 |
| WO2007128901A1 (fr) | 2007-11-15 |
| CA2650495A1 (fr) | 2007-11-15 |
| DK2029231T3 (da) | 2012-02-27 |
| EP2029231A1 (fr) | 2009-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9950013B2 (en) | Nutritional composition for improving muscle function and daily activity | |
| US20220202842A1 (en) | Compositions and methods to treat or prevent metabolic fatigue using at the compound oleuropein or a metabolite thereof | |
| US20190105371A1 (en) | Uses of casein compositions | |
| KR20200039748A (ko) | 간 질환 치료를 위한 아미노산 조성물 | |
| CA2569678C (en) | Regulator of physiological function of ghrelin and use thereof | |
| ES2377015T3 (es) | Utilización de la alfa-lactoalbúmina para la regulación de la glucemia | |
| AU771754B2 (en) | Prophylactic dietary supplement based on milk | |
| US20070196442A1 (en) | Method for improving the oral administration of alpha-lipoic acid | |
| US20060204549A1 (en) | Method of improving nutrient utilisation by a mammal and a composition for use therein | |
| ES2260500T3 (es) | Productos alimenticios ricos en mentionina modificados y procesos para su fabricacion. | |
| CN107249615B (zh) | 潮热抑制剂 | |
| Olowookere | The effect of total milk protein, casein and whey protein ingestion on blood glucose and insulin in rats | |
| WO2023213780A1 (en) | Compositions and methods using at least one of oleuropein or a metabolite thereof to treat or prevent muscle fatigue from exercise and/or for resistance to muscle fatigue from exercise | |
| AU2023263715A1 (en) | Compositions and methods using at least one of oleuropein or a metabolite thereof to treat or prevent muscle fatigue from exercise and/or for resistance to muscle fatigue from exercise | |
| Beaufrere | Optimization of dietary protein intake during aging | |
| NZ516712A (en) | Prophylactic dietary supplement based on milk |